London
· Delayed Price · Currency is GBP · Price in GBXDiaceutics Statistics
Total Valuation
Diaceutics has a market cap or net worth of GBP 105.54 million. The enterprise value is 90.08 million.
| Market Cap | 105.54M |
| Enterprise Value | 90.08M |
Important Dates
The next estimated earnings date is Thursday, September 26, 2024.
| Earnings Date | Sep 26, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Diaceutics has 84.43 million shares outstanding. The number of shares has decreased by -2.16% in one year.
| Shares Outstanding | 84.43M |
| Shares Change (YoY) | -2.16% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 27.62% |
| Owned by Institutions (%) | 57.07% |
| Float | 49.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.44 |
| PB Ratio | 2.58 |
| P/FCF Ratio | 88.99 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -51.59 |
| EV / Sales | 3.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 75.95 |
Financial Position
The company has a current ratio of 6.40, with a Debt / Equity ratio of 2.95.
| Current Ratio | 6.40 |
| Quick Ratio | 6.11 |
| Debt / Equity | 2.95 |
| Debt / EBITDA | 4.73 |
| Debt / FCF | 1.02 |
| Interest Coverage | -45.73 |
Financial Efficiency
Return on equity (ROE) is -4.19% and return on invested capital (ROIC) is -4.40%.
| Return on Equity (ROE) | -4.19% |
| Return on Assets (ROA) | -3.99% |
| Return on Capital (ROIC) | -4.40% |
| Revenue Per Employee | 128,799 |
| Profits Per Employee | -9,489 |
| Employee Count | 184 |
| Asset Turnover | 0.50 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +18.50% |
| 50-Day Moving Average | 128.63 |
| 200-Day Moving Average | 109.55 |
| Relative Strength Index (RSI) | 45.62 |
| Average Volume (20 Days) | 55,203 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diaceutics had revenue of GBP 23.70 million and -1.75 million in losses. Loss per share was -0.02.
| Revenue | 23.70M |
| Gross Profit | 19.71M |
| Operating Income | -3.02M |
| Pretax Income | -2.44M |
| Net Income | -1.75M |
| EBITDA | 102,000 |
| EBIT | -3.02M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 16.67 million in cash and 1.21 million in debt, giving a net cash position of 15.46 million or 0.18 per share.
| Cash & Cash Equivalents | 16.67M |
| Total Debt | 1.21M |
| Net Cash | 15.46M |
| Net Cash Per Share | 0.18 |
| Equity (Book Value) | 40.79M |
| Book Value Per Share | 0.48 |
| Working Capital | 23.66M |
Cash Flow
In the last 12 months, operating cash flow was 1.31 million and capital expenditures -125,000, giving a free cash flow of 1.19 million.
| Operating Cash Flow | 1.31M |
| Capital Expenditures | -125,000 |
| Free Cash Flow | 1.19M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 83.15%, with operating and profit margins of -12.73% and -7.37%.
| Gross Margin | 83.15% |
| Operating Margin | -12.73% |
| Pretax Margin | -10.29% |
| Profit Margin | -7.37% |
| EBITDA Margin | 0.43% |
| EBIT Margin | -12.73% |
| FCF Margin | 5.00% |
Dividends & Yields
Diaceutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.16% |
| Shareholder Yield | 2.16% |
| Earnings Yield | -1.66% |
| FCF Yield | 1.12% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |